<code id='A534F84445'></code><style id='A534F84445'></style>
      • <acronym id='A534F84445'></acronym>
      <center id='A534F84445'><center id='A534F84445'><tfoot id='A534F84445'></tfoot></center><abbr id='A534F84445'><dir id='A534F84445'><tfoot id='A534F84445'></tfoot><noframes id='A534F84445'>
      • <optgroup id='A534F84445'><strike id='A534F84445'><sup id='A534F84445'></sup></strike><code id='A534F84445'></code></optgroup>
        5. <b id='A534F84445'><label id='A534F84445'><select id='A534F84445'><dt id='A534F84445'><span id='A534F84445'></span></dt></select></label></b><u id='A534F84445'></u>
          <i id='A534F84445'><strike id='A534F84445'><tt id='A534F84445'><pre id='A534F84445'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / knowledge      
           
     
           
      
          knowledge 
           
      
           
      
           
       2025-09-29 08:04:32 
   
      
           
      
           
                        
          knowledge  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：5
                                  
                                    
          
                                   
          Editor’s note: A recording of the event is embedded below.
          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
          advertisement
          Featured Speakers
          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          UnitedHealth, in a surprise, takes aim at Steward’s physician group
                                
                            
          Next article：  
                                      
                                          Medicare details structure of new drug price negotiation program
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles